Bio-K Plus International is expanding its portfolio of probiotic products and is launching a new line of functional beverages infused with probiotics

Bio-K | October 22, 2020

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and modern lifestyle of today's consumer, always looking for innovative ways to stay healthy. Bio-K Plus offers a dose of probiotics in the form of fun, delightful and balanced functional beverages. This announcement is the result of more than two years of research and development carried out by Bio-K Plus' experienced team that has developed the best line of functional beverages infused with probiotic bacteria. This project was led by Martin Croteau, Chief Commercial Officer, and was driven by the need to democratize probiotics, making them more accessible for all, and broaden their use to support global health in a more holistic manner.

Spotlight

Using RNAi, scientists have developed novel crops such as nicotine-free tobacco, non-allergenic peanuts, decaffeinated coffee and nutrient fortified maize among many others--only some of which have been commercialized. Two RNAi enabled products--the now-browning Arctic Apple and the non-bruising Simplot potato--are being sold.Although much progress has been made, the full potential of RNAi for crop improvement remains to be realized, as the complexities of RNAi pathway, the molecular machineries and how it relates to plant development are still to be elucidated.


Other News
MEDICAL

Invest Ontario Supports New Biomanufacturing Facility in Hamilton

Invest Ontario | April 01, 2022

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Hamilton's McMaster Innovation Park. Subject to reaching a definitive agreement, Invest Ontario will provide a loan of up to $40 million, contributing to an overall project investment of over $580 million, creating 250 jobs by 2031. Invest Ontario will also be providing non-financial support to OmniaBio, including helping the company meet its future talent needs and promoting opportunities to enhance local skills development partnerships. As a contract manufacturer, OmniaBio will support a broad range of cell and gene therapy companies – both homegrown and international – by providing process development and clinical/commercial production services in compliance with global health standards. The OmniaBio investment supports Ontario's new Life Sciences Strategy that will advance the province's leadership as a North American life sciences hub offering a collaborative ecosystem for the development, commercialization and adoption of innovative health products and services. OmniaBio is being spun out of the Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM), a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. OmniaBio will build on CCRM's existing global client base, with the project ultimately creating a six-fold increase in biomanufacturing capacity. Ontario's life sciences sector is the largest in Canada (representing more than 50 per cent of related economic activity) and comprises about 1,900 firms employing around 66,000 people.

Read More

MEDICAL

ABC Opens Commercial MEL BioSurfactant Production in Irvine, CA

ABC | May 19, 2022

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North America. ABC pioneered the use of microbiology to produce metabolites and sustainable chemistry in 1996. Our products are used in water treatment, the energy sector, for agriculture uses, and in personal and home care applications. By using microbiology, we can create natural alternatives to petrochemicals. For our production we upcycle waste feed stocks such as used vegetable oils or other sources of bio-waste material. As a result, our chemistry also offers an alternative to plant based materials which have the unfortunate reliance on certain plant species which are contributing to global deforestation and destruction of biodiversity. The MEL material can be used in a variety of ways in the homecare and personal care sectors. MEL is free of 1,4 dioxane, mild on the skin, and produces minimal foam. This superfatting agent is ideal for delivering moisture in personal care products and can be used along with anionic and amphoteric surfactants for improved efficacy. The addition of MEL production compliments ABC's rhamnolipid and BioSS RL fermactant production. About Advanced BioCatalytics: Advanced BioCatalytics is an industrial biotechnology company that leverages its innovative Fermactant technology for applications in the Home and Personal Care, Energy, Agriculture, and Wastewater markets. These products have demonstrated the ability to be highly cost-effective, without depending on harmful chemistries such as caustics, acids or dangerous solvents, which can be harmful to the user and/or the environment. Advanced BioCatalytics was founded in 1996 and we are excited to be introducing a new technology that will change the future performance, and cost, of the world's cleaning products.

Read More

INDUSTRIAL IMPACT

EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies

Eyebiotech Limited | February 23, 2022

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking ophthalmology therapies. EyeBio launches with a specific mission: to protect, restore, and improve vision for people who are underserved by available eye disease therapies. The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches. The company has established a footprint in the United Kingdom to take advantage of the innovation-friendly environment for its clinical trial development. EyeBio welcomes inquiries regarding in-licensing and acquisition of assets into its portfolio. “Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs. Patients and physicians deserve new and better solutions, which is why this team of serial disruptors has banded together to form EyeBio. We are launching at an exciting time, and we are equipped with the resources to make a significant impact.” Dr. Guyer, Co-Founder, President, and Chief Executive Officer of EyeBio “EyeBio is well positioned to improve outcomes for patients by addressing a segment of ophthalmology that needs further innovation,” said Dr. Adamis, Co-Founder, Director, and Chair of the Advisory Board of EyeBio. “Success requires an ability to execute and deliver new therapies with speed and quality. EyeBio has the talent, skillset, and willingness to introduce new solutions to address familiar problems.” Prior to co-founding EyeBio, Dr. Guyer served as executive chairman and CEO of Iveric Bio, a biopharmaceutical company developing novel treatments for retinal diseases. Dr. Adamis previously served as Senior Vice President of Development Innovation at Genentech, a member of The Roche Group. Over his career, he led development programs in multiple therapeutic areas and oversaw 25 U.S. Food and Drug Administration (FDA) approvals. About EyeBio Eyebiotech Limited is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. Founded in August 2021 by David Guyer, M.D., and Anthony P. Adamis, M.D., EyeBio has a leadership team composed of serial disruptors in ophthalmology drug development. With operations in the United States and the United Kingdom, EyeBio is building and advancing a pipeline of ocular therapies that combine scientifically robust targets with innovative translational approaches. About SV Health Investors SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV family of funds invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.7 billion in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, M.D., Ph.D., our team of scientists, investors, and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies. Samsara actively manages over US $1 billion in assets on behalf of endowments, foundations, and family offices. About Jeito Capital Jeito Capital is a global leading investment company with a patient benefit-driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe and the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. About MRL Ventures MRL Ventures Fund (MRLV) is the therapeutics-focused corporate venture fund of Merck & Co., Inc., with headquarters in Kenilworth, N.J., USA. From its headquarters in Cambridge, Mass., USA, the MRLV team invests globally in early-stage innovative therapeutics companies that are developing transformative medicines in any therapeutic area using any modality. The MRLV team of experienced life-sciences venture capital professionals is committed to supporting great entrepreneurs in their quest to create value through building companies that have a meaningful impact on health and disease.

Read More

INDUSTRIAL IMPACT

Lummus and Synthos Advance Bio-Butadiene Technology Development to Produce Sustainable Rubber

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for renewable materials, Synthos has committed to building a plant with a capacity of 40,000 metric tons of bio-butadiene per year – twice as much as the companies had originally planned. In addition to the plant capacity expansion, Synthos has confirmed that it will license BASF's butadiene extraction technology from Lummus and leverage Lummus' digitalization capabilities for operational efficiency and reliability. "Since Lummus began collaborating with Synthos last year, it has become evident that this technology has the potential to be the new standard in our industry due to its renewable sourcing, production efficiency and low carbon footprint. The petrochemical industry is quickly adjusting to ambitious sustainability requirements, and at Lummus we continue to lead this change on multiple fronts. The commercialization with Synthos of this bio-technology for more sustainable rubber products is one of several sustainable process solutions that are making a positive impact." Leon de Bruyn, President and Chief Executive Officer of Lummus Technology "Synthos is making great strides in developing a synthetic rubber product portfolio with a significantly reduced environmental footprint. Entering the next phase of our collaboration with Lummus is another step toward our commitment to help our customers achieve their performance and sustainability goals," said Matteo Marchisio, Synthetic Rubber Business Unit Director, Synthos. "We believe the availability of sustainable synthetic rubber made from bio-butadiene will play an important role in the industry's ability to meet the demands of modern mobility, and we are proud to partner with Lummus Technology to lead the way." Synthos is a global leader in the development and production of synthetic rubber for tires and technical rubber goods and is committed to providing its customers with high-performance material solutions with a lower environmental footprint. In 2021, Green Circle and Synthos announced that they will collaborate on the development and commercialization of bio-butadiene derived from bio-ethanol to enable the production of value-added, more sustainable synthetic rubber. A subsidiary of Lummus, Green Circle is a leader in commercializing and developing breakthrough solutions to address the key pillars of the energy transition, including end-of-life waste plastics recycling, production of bio derived sustainable chemicals, and decarbonization strategies for existing and new assets. About Lummus Technology Lummus Technology is the global leader in developing process technologies that make modern life possible and focus on a more sustainable, low carbon future. Lummus is a master licensor of clean energy, petrochemical, refining, gas processing and renewable technologies, and a supplier of catalysts, proprietary equipment, digitalization and related lifecycle services to customers worldwide. About Synthos Synthos S.A. is a chemical producer and a major player in the global synthetic rubber market. Synthos S.A. Capital Group's business includes the production and sales of chemical products used as raw materials and intermediates in a wide range of industries, particularly in the tire industry, the construction industry and the packaging industry.

Read More

Spotlight

Using RNAi, scientists have developed novel crops such as nicotine-free tobacco, non-allergenic peanuts, decaffeinated coffee and nutrient fortified maize among many others--only some of which have been commercialized. Two RNAi enabled products--the now-browning Arctic Apple and the non-bruising Simplot potato--are being sold.Although much progress has been made, the full potential of RNAi for crop improvement remains to be realized, as the complexities of RNAi pathway, the molecular machineries and how it relates to plant development are still to be elucidated.

Resources